STOCK TITAN

Personalis (PSNL) Stock News, Apr-Jul 2025

PSNL NASDAQ

Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.

News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.

Rhea-AI Summary

Personalis (Nasdaq: PSNL), a genomics company focused on cancer research, has scheduled the release of its Q2 2025 financial results for Tuesday, August 5, 2025. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day.

Investors can join via phone using the following dial-in numbers: 877-451-6152 (domestic) or 201-389-0879 (international). A webcast will be available in the Events section at investors.personalis.com, with a replay archived on the website after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
-
Rhea-AI Summary

Personalis (Nasdaq: PSNL), a precision oncology genomics company, has granted an inducement stock option to its newly appointed Vice President, Corporate Controller. The option allows for the purchase of 100,000 shares of common stock at an exercise price of $6.31 per share, matching the closing price on July 15, 2025.

The stock option, granted under Personalis' 2020 Inducement Plan, follows a four-year vesting schedule with 25% vesting after one year and the remaining portions vesting monthly over the following three years, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary

Personalis (Nasdaq: PSNL) has expanded and extended its strategic collaboration with Tempus AI through 2029, adding colorectal cancer (CRC) as the fourth indication for their NeXT Personal® minimal residual disease (MRD) test. The test will now cover breast, lung, and colorectal cancers, plus solid tumor immunotherapy monitoring.

The expansion follows promising interim results from the VICTORI study presented at AACR 2025, showing strong performance in detecting early CRC recurrence. The collaboration leverages Tempus' extensive network reaching over 50% of U.S. oncologists to accelerate the adoption of Personalis' ultra-sensitive cancer recurrence detection technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
none
Rhea-AI Summary
Personalis (PSNL) presented groundbreaking results from the CALLA phase 3 study demonstrating their NeXT Personal blood test's ability to detect cervical cancer recurrence up to 16 months before traditional imaging. The study, analyzing ctDNA in blood samples from 186 locally advanced cervical cancer patients, revealed that ctDNA levels post-chemoradiotherapy strongly predicted cancer progression risk. Key findings showed patients without detectable ctDNA ~3 months after treatment had 95% lower risk of progression and death. The test detected disease progression approximately 5 months earlier than imaging scans, with some cases detected up to 16 months earlier. High baseline ctDNA levels correlated with increased progression and mortality risks. This breakthrough could significantly impact treatment decisions for cervical cancer, which remains the fourth most common cancer among women globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.53%
Tags
-
Rhea-AI Summary
Personalis (PSNL) announced significant clinical results demonstrating the effectiveness of its NeXT Personal blood test in monitoring triple negative breast cancer (TNBC) patients. The data from PREDICT DNA and SCANDARE studies shows that the ultrasensitive circulating tumor DNA (ctDNA) test can identify high-risk patients for relapse after neoadjuvant therapy. Key findings revealed that patients with detectable ctDNA post-neoadjuvant therapy were approximately 10 times more likely to relapse, and those with post-surgical ctDNA detection were over 85 times more likely to experience recurrence. The test demonstrated 100% detection rate in pretreatment samples and showed particular strength in ultrasensitive detection below 100 PPM. The results suggest NeXT Personal could be instrumental in guiding clinical decisions for additional adjuvant therapies, with potential implications for reimbursement coverage in breast cancer monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
-
Rhea-AI Summary

Personalis (NASDAQ: PSNL) announced multiple presentations at the upcoming ASCO Annual Meeting in Chicago, showcasing new clinical data for their NeXT Personal® ultrasensitive ctDNA assay. The presentations focus on detecting residual and recurrent cancer across various applications, including breast cancer and cervical cancer.

The company will present four studies: a clinical science symposium on circulating tumor DNA in breast cancer (PREDICT-DNA trial), an oral presentation on ctDNA detection in locally advanced cervical cancer (CALLA trial), and two poster presentations covering triple-negative breast cancer post-chemotherapy and immunotherapy monitoring in advanced cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences
Rhea-AI Summary

Personalis (NASDAQ: PSNL), a company specializing in advanced genomics for precision oncology, has announced its management team's participation in the upcoming Craig-Hallum 22nd Annual Investor Conference. The event is scheduled to take place on Wednesday, May 28, 2025, and will be held at The Depot Renaissance Hotel in Minneapolis, MN.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
conferences
-
Rhea-AI Summary
Personalis (PSNL) reported Q1 2025 financial results with revenue of $20.6 million, up 6% year-over-year. The company delivered 2,184 molecular tests, a 52% sequential increase. Pharma tests and services revenue grew 39% to $13.6 million, while population sequencing revenue decreased 29% to $6.7 million. Gross margin improved to 35% from 28.1%. The company reported a net loss of $15.8 million ($0.18 per share). Notable achievements include positive results from NeXT Personal studies in colorectal and breast cancer, with 100% detection rate for eventual recurrences. For full-year 2025, Personalis expects revenue of $80-90 million and projects a net loss of approximately $83 million. The company ended Q1 with $185.7 million in cash and equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.00%
Tags
-
Rhea-AI Summary

Personalis announced breakthrough results from their VICTORI cancer study, demonstrating that their NeXT Personal assay achieved 100% success in detecting colorectal cancer relapses before traditional imaging methods. The study, conducted at BC Cancer in Vancouver, analyzed blood samples from 71 patients with Stage I-IV colorectal cancer.

Key findings include:

  • 100% detection rate of cancer recurrence before imaging confirmation
  • 87% of relapses detected within 8 weeks post-surgery
  • 85% of cases detected by 4 weeks post-surgery
  • 100% accuracy in identifying disease-free patients
  • Successful detection of distant metastases, including challenging lung metastasis
  • 70% of initial detections were ultra-sensitive, with measurements as low as 2.45 PPM

The study, with a median follow-up of 15.75 months, highlights the potential of ctDNA-based liquid biopsies to help identify patients needing additional treatment while potentially helping others avoid unnecessary chemotherapy. The research continues as researchers aim to improve early cancer recurrence detection and treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
Rhea-AI Summary

Personalis (Nasdaq: PSNL), a leader in advanced genomics for cancer, has scheduled the release of its first quarter 2025 financial results on Tuesday, May 6, 2025. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day to discuss the results and recent highlights.

Participants can join the call by dialing 877-451-6152 (domestic) or 201-389-0879 (international). The webinar will be accessible through the Events section on the company's investor website, with a replay available shortly after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags

FAQ

What is the current stock price of Personalis (PSNL)?

Personalis (PSNL) last closed at $14.80.

What is the market cap of Personalis (PSNL)?

The market cap of Personalis (PSNL) is approximately $1.6B.